Suricog
Entity
Description
  • Value proposition

    SuriCog was founded in mid-2013 by Marc Massonneau, serial entrepreneur in medical devices & services, and some other passionate people, to develop new generation of gaze-based diagnostic tools in order to improve patient pathways in neurology and psychiatry. In 2016, we acquired a company which developed a 10M€ program for best-in-class eye-movement acquisition and analysis solutions in several key neurological diseases
    Drawing from over a quasi-decade of eye studies, algorithm development, optoelectronics design, high-end software, and clinical trials and applications, we have advanced our technology for integration in a data-driven complete solution, as the fundamental for medical oriented eye-tracking. The aim is to approach the most complex organ, the brain, with the right tools for a simple and efficient integration of advanced research into daily medical practice.
    SuriCog now has more than 20 issued and pending patents, nearly 100 scientific publications with results in ten neuro-diseases and is present in more than 10 countries. And all developments are carried out in strict accordance with medical regulations.
    The SuriCog team has over 90 years of combined experience in medical device, drug development, clinical trials, market access, engineering, sales operations, and, moreover, imbued with in-depth neuroscientific expertise and medical empathy.


    eyetracking, medical device, IHM, dispositif médical, électonique embarquée, neurologie, and dyslexie

  • Original language

    SuriCog was founded in mid-2013 by Marc Massonneau, serial entrepreneur in medical devices & services, and some other passionate people, to develop new generation of gaze-based diagnostic tools in order to improve patient pathways in neurology and psychiatry. In 2016, we acquired a company which developed a 10M€ program for best-in-class eye-movement acquisition and analysis solutions in several key neurological diseases
    Drawing from over a quasi-decade of eye studies, algorithm development, optoelectronics design, high-end software, and clinical trials and applications, we have advanced our technology for integration in a data-driven complete solution, as the fundamental for medical oriented eye-tracking. The aim is to approach the most complex organ, the brain, with the right tools for a simple and efficient integration of advanced research into daily medical practice.
    SuriCog now has more than 20 issued and pending patents, nearly 100 scientific publications with results in ten neuro-diseases and is present in more than 10 countries. And all developments are carried out in strict accordance with medical regulations.
    The SuriCog team has over 90 years of combined experience in medical device, drug development, clinical trials, market access, engineering, sales operations, and, moreover, imbued with in-depth neuroscientific expertise and medical empathy.

  • Suricog - Oculomotricité eye-tracking et Eyebrain à vocation médicale.

    Medtech spécialiste de l’oculomotricité eye-tracking à vocation médicale. Quantifier les troubles cérébraux dans une pratique clinique.

    • https://www.suricog.com/
  • Website is disabled or domain is for sale
Corporate interactions BETA
Corporate TypeTweets Articles
AbbVie
AbbVie
Pharmaceutical, Pharmaceutical Manufacturing
AbbVie
Pharmaceutical, Pharmaceutical Manufacturing 		Other
Ipsen
Ipsen
Pharmaceutical, Pharmaceutical Manufacturing
Ipsen
Pharmaceutical, Pharmaceutical Manufacturing 		Other
BioValley France
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research 		Other

31 Mar 2024


SEMIA
SEMIA
Startup accelerator & VC, Business Consulting and Services
SEMIA
Startup accelerator & VC, Business Consulting and Services 		Other

9 Feb 2024


Similar entities
Last news
Show all articles
Social network dynamics